NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Peterson K, McDonagh M, Thakurta S, et al. Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet]. Portland (OR): Oregon Health & Science University; 2010 Nov.
This publication is provided for historical reference only and the information may be out of date.
Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet].
Show details| Drug names | Boxed warnings |
|---|---|
| Celebrex®, Zipsor®, Cataflam®, Nalfon®, Ansaid®, Indocin®, Indocin SR®, Mobic®, Naprosyn®, EC-Naprosyn®, Anaprox®, Anaprox® DS, Naprelan®, Daypro®, Feldene®, Clinoril®, Tolectin® DS, Tolectin® 600, Flector®, Pennsaid®, Ponstel®, Tolectin®, Voltaren®a | Cardiovascular Risk
|
| Voltaren SR, Voltaren Rapide, Ponstan®, Mobicox®, Naprosyn E®, Naprosyn SR®b |
|
- a
Not available in Canada, available in the United States.
- b
Available in Canada, not available in the United States.
- Black Box Warnings of Included Drugs - Drug Class Review: Nonsteroidal Antiinfla...Black Box Warnings of Included Drugs - Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs)
- Physiology, Fasting - StatPearlsPhysiology, Fasting - StatPearls
- Chronic Inflammation - StatPearlsChronic Inflammation - StatPearls
- Summary - Relieving Pain in AmericaSummary - Relieving Pain in America
- Dose-response characteristics of cholesterol-lowering drug therapies: implicatio...Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...